Deep Brain Stimulation of the Medial Forebrain Bundle and Subcallosal Cingulate for the Treatment of Treatment Resistant Depression
Active stimulation of the medial forebrain bundle or subcallosal cingulate
+ Sham stimulation
Troubles Mentaux+1
+ Trouble Dépressif
+ Troubles de l'humeur
Étude thérapeutique
Résumé
Date de début de l'étude : 15 juin 2019
Date à laquelle le premier participant a commencé l'étude.Eight patients with TRD will be treated with DBS to the MFB. At approximately 2 weeks postoperartively, stimulation will be initiated in all patients. Voltage and contact position will be altered initially, looking for optimal and stabilized responses in depressive symptoms, while trying to minimize any side effects. Following this 6 month open-label optimization phase, patients will be then undergo randomization to receive 2 weeks of stimulation followed by 2 weeks of sham stimulation, or vice versa. These 2 week phases will be separated by a 1 week washout period. Depressive symptoms will be evaluated at the end of each 2 week phase, then patients will resume open-label stimiulation.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.10 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.De 20 à 80 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: 1. Men and women ≥20 and ≤80 years of age. 2. Patients who are able and willing to give consent and physically and practically able to attend study visits, as determined by both study Psychiatrist and the surgeon. 3. DSM-V diagnosis of major depressive disorder or bipolar II, 4. At least 5-year illness history of the primary disorder and at least 6 months since the onset of the first episode of major depression. 5. A minimum score of 20 on the Hamilton Depression Rating Scale (HAMD) when depressed) 6. Medication-refractoriness as determined by an adequate dose and duration of standard psychiatric treatments (including psychotherapy and/or pharmacology) as determined by two psychiatrists associated with the study. Including specifically: 1. Failed to respond or tolerate adequate trial of three or more medications accepted as first line in the treatment of depression 2. Failed to respond or tolerate augmentation with or combination of at least 2 medications known to be first line treatments for depression 3. An adequate trial of cognitive behavioural therapy or other evidence-supported psychotherapy, delivered by a therapist experienced in treating depression 7. A consistent dose of any and all medications in the 30 days prior to study entry. 8. Women of childbearing potential must agree to use a contraception method throughout the study. Exclusion Criteria: 1. Past or current evidence of psychosis or mania 2. Active neurologic disease, such as epilepsy 3. Alcohol or substance dependence or abuse in the last 6 months, excluding caffeine and nicotine 4. Current active suicidal ideation 5. Any contraindication to MRI scanning 6. Presence of significant cognitive impairment 7. Likely to relocate or move out of the country during the study's duration 8. Presence of clinical and/or neurological conditions that may significantly increase the risk of the surgical procedure. 9. Currently pregnant (as determined by history and serum HCG) or lactating; for females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.2 groupes d'intervention sont désignés dans cette étude
50% de chances d'être dans le groupe placebo en aveugle
Groupes de traitement
Groupe I
ExpérimentalGroupe II
Dispositif fictifObjectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site
Sunnybrook Health Sciences Center
Toronto, CanadaOuvrir Sunnybrook Health Sciences Center dans Google Maps